Andreas du Bois

from Wikipedia, the free encyclopedia
Andreas du Bois (2018)

Andreas du Bois (* 1956 in Frankfurt am Main ) is a German gynecologist and oncologist. He is the director of the Clinic for Gynecology & Gynecological Oncology at the Cancer Center an den Evang. Essen-Mitte clinics as well as founder and study leader of the Gynecological Oncology Working Group (AGO) study group.

Life

From 1976 to 1978 Andreas du Bois studied philosophy with the minor subjects psychology , history , political science and religious studies at the Free University of Berlin . From 1981 to 1987 he studied human medicine at the Albert Ludwig University of Freiburg . There he received his doctorate in 1987. After a brief activity in surgery at the Wolfach district hospital, du Bois completed his advanced training as a gynecologist at the Freiburg University Women's Clinic.

1993 became leading senior physician at the Vincentius hospitals in Karlsruhe . It was completed in 1997 after postdoctoral the instructor for the subject Gynecology of the University of Freiburg awarded. In 1999, Andreas du Bois was appointed Clinic Director of the Clinic for Gynecology and Gynecological Oncology at the Dr. Horst Schmidt Clinics in Wiesbaden , where he set up the largest gynecological oncological center in Hesse . In 2004 he was after Umhabilitation for at the Gutenberg University in Mainz as professor appointed and received in 2005 the call to the chair of gynecology at the Medical School Hannover . In the course of more than a year of negotiations, however, no agreement was reached, so he stayed in Wiesbaden. On January 1, 2011, he moved to Evang. Essen-Mitte clinics.

His scientific career began after completing his doctorate in 1987 in the University Women's Clinic in Freiburg. There he also began the work that ultimately led to his habilitation in 1997 : The role of serotonin and cortisol metabolism in the pathophysiology of vomiting. His work contributed to the introduction of the 5HT 3 receptor antagonists in the therapy and prophylaxis of chemotherapy-induced nausea and vomiting.

Research focus

His research focus is on gynecological oncology. In 1993 he founded the AGO study group (then: AGO-OVAR) together with four other senior physicians.

In this group, he combined more than 300 women's clinics in Germany and thus created the infrastructure for cooperative clinical studies of phases I-IV. The third study (“AGO-OVAR 3”) recruited patients from 1995 to 1997 and led to the establishment of carboplatin-paclitaxel as the new, global standard therapy for advanced ovarian cancer .

In further studies, the standards of relapse therapy with platinum combinations were established and new therapy regimes were developed, such as: B. Carboplatin Gemcitabine. In the case of an early relapse with an unfavorable prognosis, the study group was able to show that hormone therapy is inferior to chemotherapy.

In the operative study LION it could be shown that the systematic removal of the lymph nodes ("lymphadenectomy") does not bring any advantages, but only more side effects in advanced ovarian cancer . Another work, cited more than 1000 times, demonstrated the prognostically favorable value of complete surgical resection in the treatment of ovarian cancer. In the DESKTOP 1-3 surgical study series on the question of relapse surgery in ovarian cancer, a score was developed that identifies patients for whom such an operation appears suitable. In the prospective randomized study, a survival advantage for the patients identified and operated on was ultimately shown.

In addition to the clinical studies, there was another focus of research in the field of health services research and quality assurance .

Prizes and awards

Memberships, honorary positions and functions in scientific societies

  • American Society of Clinical Oncology (ASCO)
  • Gynecologic Cancer International Intergroup (GCIG)
    • Member of the Executive Board and representative of AGO-OVAR
    • Chairman of the 3rd International Ovarian Cancer Consensus Conference
    • Scientific Board 2nd, 3rd, 4th and 5th Consensus Conference
    • Member of the Working Group Classifications , here: Development of the CA 125 response criteria
  • European Network of Gynecologic Oncology Trial Groups (ENGOT)
    • Founder (together with I. Vergote), President 2012 - 2014
  • European Society of Gynecologic Oncology (ESGO)
    • Member of the Board of Management (2003 - 2007)
    • Chair of the relapse therapy working group at the 1st European ESMO / ESGO Consensus Conference on Ovarian Cancer 2018
    • Task Force Certification of Centers of Excellence and ESGO Centers for Ovarian Cancer Surgery
    • Working group consensus meeting on the therapy of malignancies in pregnancy
  • German Society for Gynecology and Obstetrics (DGGG)
  • German Cancer Society (DKG)
    • Founding chairman of the working group supportive measures in oncology of the German Cancer Society
    • Member of the Clinical Studies Commission (representative of the AGO 2002-2004)
    • Member of the S3 guideline commissions for ovarian cancer and breast cancer
  • Working group gynecological oncology (AGO) in the DKG and DGGG
    • Founding member of the OVAR organ committee
    • Head of the quality assurance program QS-OVAR since 2000
  • Founder, director of studies and executive board of the AGO study group
  • Member of the board of Menschenwohlers eV , an association in Essen for families with children in which one of the parents is affected by cancer

Publications

  • Editorial Board (current and former): J Clin Oncol, Gynecol Oncol, Int J Gynecol Cancer, Onkologie, J Support Care Cancer, Oncology Reports u. a. m.
  • More than 500 publications in peer-reviewed journals with over 27,000 citations and an h-index of 76

Web links

Individual evidence

  1. ↑ team. Retrieved March 9, 2020 .
  2. ↑ Profile. In: AGO Research GmbH. Retrieved March 9, 2020 .
  3. ↑ A. du Bois, HG Meerpohl, FGM Kommoss, A. Pfleiderer, W. Vach: Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron . In: European Journal of Cancer . tape 28 , no. 2-3 , February 1992, pp. 450–457 , doi : 10.1016 / S0959-8049 (05) 80075-9 ( elsevier.com [accessed March 9, 2020]).
  4. ^ A du Bois, W Vach, U Wechsel, R Holy, W Schaefer: 5-Hydroxyindoleacetic acid (5-HIAA) and cortisol excretion as predictors of chemotherapy-induced emesis . In: British Journal of Cancer . tape 74 , no. October 7 , 1996, ISSN  0007-0920 , pp. 1137–1140 , doi : 10.1038 / bjc.1996.503 , PMID 8855988 , PMC 2077123 (free full text) - ( nature.com [accessed March 9, 2020]).
  5. ^ A. du Bois, J. Rochon, C. Lamparter, G. Elser, J. Pfisterer: Supply structure, quality assurance and clinical studies in invasive ovarian cancer in Germany - the AGO's QS-OVAR action program and the activities of the AGO study group . In: Management of Ovarian Cancer . Springer Berlin Heidelberg, Berlin, Heidelberg 2009, ISBN 978-3-540-41987-7 , pp. 325–338 , doi : 10.1007 / 978-3-540-68857-0_22 ( springer.com [accessed March 9, 2020]).
  6. ↑ A. du Bois, H.-J. Lück, T. Bauknecht, V. Möbus, H. Bochtler: Phase I / II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer . In: Annals of Oncology . tape 8 , no. 4 , April 1997, ISSN  0923-7534 , p. 355–361 , doi : 10.1023 / a: 1008267419453 ( annalsofoncology.org [PDF; accessed March 9, 2020]).
  7. ^ Andreas du Bois, Hans-Joachim Lück, Werner Meier, Hans-Peter Adams, Volker Möbus: A Randomized Clinical Trial of Cisplatin / Paclitaxel Versus Carboplatin / Paclitaxel as First-Line Treatment of Ovarian Cancer . In: JNCI: Journal of the National Cancer Institute . tape 95 , no. 17 , September 3, 2003, ISSN  0027-8874 , p. 1320-1329 , doi : 10.1093 / jnci / djg036 ( oup.com [accessed March 9, 2020]).
  8. ^ Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4 / AGO-OVAR-2.2 trial . In: The Lancet . tape 361 , no. 9375 , June 2003, p. 2099–2106 , doi : 10.1016 / S0140-6736 (03) 13718-X ( elsevier.com [accessed March 9, 2020]).
  9. ↑ J. Pfisterer, M. Plante, I. Vergote, A. Du Bois, U. Wagner: Gemcitabine / carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG . In: Journal of Clinical Oncology . tape 22 , 14_suppl, July 15, 2004, ISSN  0732-183X , p. 5005–5005 , doi : 10.1200 / jco.2004.22.90140.5005 ( ascopubs.org [accessed March 9, 2020]).
  10. ^ A. du Bois, W. Meier, HJ Lück, G. Emons, V. Moebus: Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomized trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer . In: Annals of Oncology . tape 13 , no. 2 , February 2002, p. 251-257 , doi : 10.1093 / annonc / mdf038 ( elsevier.com [accessed March 9, 2020]).
  11. ↑ Philip Harter, Jalid Sehouli, Domenica Lorusso, Alexander Reuss, Ignace Vergote: A Randomized Trial of lymphadenectomy in Patients with Advanced Ovarian Neoplasms . In: New England Journal of Medicine . tape 380 , no. 9 , February 28, 2019, ISSN  0028-4793 , p. 822-832 , doi : 10.1056 / NEJMoa1808424 ( nejm.org [accessed March 9, 2020]).
  12. ↑ Andreas du Bois, Alexander Reuss, Eric Pujade ‐ Lauraine, Philipp Harter, Isabelle Ray ‐ Coquard: Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials . In: Cancer . tape 115 , no. 6 , 2009, ISSN  1097-0142 , p. 1234–1244 , doi : 10.1002 / cncr.24149 ( wiley.com [accessed March 9, 2020]).
  13. ↑ Philipp Harter, Andreas du Bois, Maik Hahmann, Annette Hasenburg, Alexander Burges: Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial . In: Annals of Surgical Oncology . tape 13 , no. 12 , December 11, 2006, ISSN  1068-9265 , p. 1702–1710 , doi : 10.1245 / s10434-006-9058-0 ( springer.com [accessed March 9, 2020]).
  14. ↑ Philippe Van Trappen: F1000Prime recommendation of Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Commission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. February 13, 2011, accessed March 9, 2020 .
  15. ↑ Andreas Du Bois, Ignace Vergote, Gwenael Ferron, Alexander Reuss, Werner Meier: Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III / ENGOT ov20. In: Journal of Clinical Oncology . tape 35 , 15_suppl, May 20, 2017, ISSN  0732-183X , p. 5501–5501 , doi : 10.1200 / JCO.2017.35.15_suppl.5501 ( ascopubs.org [accessed March 9, 2020]).
  16. ^ A du Bois, J Rochon, C Lamparter, J Pfisterer: The quality assurance program of the AGO Organ Commission OVAR (QS-OVAR): Supply structure and reality in Germany 2001 . In: Zentralblatt für Gynäkologie . tape 127 , no. 01 , February 9, 2005, ISSN  0044-4197 , p. 9–17 , doi : 10.1055 / s-2005-836289 ( thieme-connect.de [accessed on March 9, 2020]).
  17. ^ A. Du Bois, J. Rochon, C. Lamparter, J. Pfisterer: Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer . In: International Journal of Gynecologic Cancer . tape 15 , no. 2 , 2005, ISSN  1048-891X , p. 183-191 , doi : 10.1136 / ijgc-00009577-200503000-00001 ( bmj.com [accessed March 9, 2020]).
  18. ↑ du Bois A, Lück HJ, Pfisterer J et al. Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer - a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group. Ann Oncol, 12: 1115-1120, 2001. Retrieved March 9, 2020 .
  19. ↑ Download / Links ›Press Releases | AGO study group | AGO Research GmbH. Retrieved March 9, 2020 .
  20. ^ Ago Austria: Wertheim Prize. Retrieved March 9, 2020 .
  21. ↑ Article Deutsches Ärzteblatt. Retrieved March 9, 2020 .
  22. ↑ https://www.geicogroup.com/wp-content/uploads/ProgramaMDAnderson2016.pdf. Retrieved March 9, 2020 .
  23. ^ Medical University of Vienna: Adjunct Professorships | Studied at the MedUni Vienna. Retrieved March 9, 2020 .
  24. ↑ Nya hedersdoktorer vid Medicinska fakulteten i Lund 2016. February 25, 2016, accessed on March 9, 2020 (Swedish).
  25. ↑ https://basel.krebsliga.ch/news/pages/2018/einladen-der-frauenklinik-des-universitaetsspital-basel/-dl-/fileadmin/krebsliga_beider_basel/downloads/sheets/53-jahresfortbildungsveranstaltung-Frauenklinik.pdf. Retrieved March 9, 2020 .
  26. ↑ https://www.ous-research.no/dgo/docs/Trope-meetings/Trope-meeting-2018.pdf. Retrieved March 9, 2020 .
  27. ^ German Cancer Society - German Cancer Prize - German Cancer Society. Retrieved March 9, 2020 .
  28. ↑ JS Berek, K. Bertelsen, A. du Bois, MF Brady, J. Carmichael: Advanced epithelial ovarian cancer: 1998 consensus statements . In: Annals of Oncology . tape 10 , 1999, p. S87 – S92 , doi : 10.1016 / S0923-7534 (20) 31491-5 ( elsevier.com [accessed March 9, 2020]).
  29. ^ A. du Bois, M. Quinn, T. Thigpen, J. Vermorken, E. Avall-Lundqvist: 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) . In: Annals of Oncology . tape 16 , 2005, pp. viii7 – viii12 , doi : 10.1093 / annonc / mdi961 ( elsevier.com [accessed March 9, 2020]).
  30. ↑ Gavin CE Stuart, Henry Kitchener, Monica Bacon, Andreas duBois, Michael Friedlander: 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference . In: International Journal of Gynecologic Cancer . tape 21 , no. 4 , April 1, 2011, ISSN  1048-891X , doi : 10.1097 / IGC.0b013e31821b2568 , PMID 21543936 ( bmj.com [accessed March 9, 2020]).
  31. ↑ MK Wilson, E. Pujade-Lauraine, D. Aoki, MR Mirza, D. Lorusso: Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease . In: Annals of Oncology . tape 28 , no. 4 , April 2017, p. 727-732 , doi : 10.1093 / annonc / mdw663 , PMID 27993805 , PMC 6246494 (free full text) - ( elsevier.com [accessed March 9, 2020]).
  32. ^ Gordon JS Rustin, Michael Quinn, Tate Thigpen, Andreas du Bois, Eric Pujade-Lauraine: Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer) . In: JNCI: Journal of the National Cancer Institute . tape 96 , no. 6 , March 17, 2004, ISSN  1460-2105 , p. 487-488 , doi : 10.1093 / jnci / djh081 ( oup.com [accessed March 9, 2020]).
  33. ^ Gordon John Sampson Rustin, Ignace Vergote, Elizabeth Eisenhauer, Eric Pujade-Lauraine, Michael Quinn: Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG) . In: International Journal of Gynecologic Cancer . tape 21 , no. 2 , January 1, 2011, ISSN  1048-891X , doi : 10.1097 / IGC.0b013e3182070f17 ( bmj.com [accessed March 9, 2020]).
  34. ↑ https://www.openaccessjournals.com/articles/the-european-network-of-gynecological-oncology-trial-groups.pdf. Retrieved March 9, 2020 .
  35. ↑ Andreas du Bois, Alexander Reuss, Eric Pujade-Lauraine, Sandro Pignata, Jonathan Ledermann: European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Industry Partners — First Update 2015 . In: International Journal of Gynecologic Cancer . tape 25 , no. 7 , September 1, 2015, ISSN  1048-891X , doi : 10.1097 / IGC.0000000000000478 , PMID 26067859 ( bmj.com [accessed March 9, 2020]).
  36. ↑ N Colombo, C Sessa, A du Bois, J Ledermann, Wg McCluggage: ESMO – ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumors and recurrent disease . In: International Journal of Gynecologic Cancer . tape 29 , no. 4 , May 2019, ISSN  1048-891X , p. 728–760 , doi : 10.1136 / ijgc-2019-000308 ( bmj.com [accessed March 9, 2020]).
  37. ↑ Denis Querleu, François Planchamp, Luis Chiva, Christina Fotopoulou, Desmond Barton: European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery . In: International Journal of Gynecologic Cancer . tape 26 , no. 7 , September 1, 2016, ISSN  1048-891X , doi : 10.1097 / IGC.0000000000000767 , PMID 27648648 ( bmj.com [accessed March 9, 2020]).
  38. ↑ Frédéric Amant, Kristel Van Calsteren, Michael J. Halaska, Jos Beijnen, Lieven Lagae: Gynecologic Cancers in Pregnancy: Guidelines of an International Consensus Meeting . In: International Journal of Gynecologic Cancer . tape 19 , S1, May 1, 2009, ISSN  1048-891X , doi : 10.1111 / IGC.0b013e3181a1d0ec , PMID 19509538 ( bmj.com [accessed March 9, 2020]).
  39. ↑ https://www.karger.com/Article/PDF/27072. Retrieved March 9, 2020 .
  40. ↑ Bauknecht T, Breitbach GP, du Bois A et al .: Malignant ovarian tumors . In: Deutsche Krebsgesellschaft eV, Quality Assurance in Oncology, Brief Interdisciplinary Guidelines 2000 . W. Zuckschwerdt Verlag, Munich 2000, p. 301-318 .
  41. ↑ du Bois A, Burges A, Emons G, et al .: Interdisciplinary S2k guideline for the diagnosis and treatment of malignant ovarian tumors 2007 . In: Schmalfeldt B, Pfisterer J (ed.): Commission Ovar of AGO eV W. Zuckschwerdt Verlag, Munich 2007.
  42. ↑ Kreienberg R, Kopp I, Albert U, Bartsch HH, Beckmann MW, Berg D, Bick U, du Bois A et al: Interdisciplinary S3 guideline for diagnostics . In: DKG and DGGG (eds.): Therapy and follow-up care of breast cancer . W. Zuckschwerdt Verlag, Munich 2008.
  43. ↑ www.xn--menschenmgliches-uwb.de/ueber-uns. Retrieved March 9, 2020 .
  44. ↑ Google Scholar 1/2020 - see web links
personal data
SURNAME Bois, Andreas you
BRIEF DESCRIPTION German gynecologist and oncologist
DATE OF BIRTH 1956
PLACE OF BIRTH Frankfurt am Main